Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

232.06 +4.65 (+2.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Benzinga's Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More
Benzinga has examined the prospects for many investor favorite stocks over the pas... 
Via Benzinga
Nvidia And Dollar Tree Lead The Nasdaq In A Mixed Day For The Markets
U.S. indices had another mixed day of trading following worse-than-expected U.S. jobless figures and inflation data released Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
Why Biogen Shares Are Trading Higher Today
Biogen Inc (NASDAQ:BIIB) shares are trading higher by 3.2%... 
Via Benzinga
Biogen Sinks Despite Raft of Analyst Upgrades
The Aduhelm effect seems to be quickly wearing off the stock. 
Via The Motley Fool
BIIB Stock: 9 Things to Know About Biogen’s Alzheimer Drug Approval Controversy
Biogen (BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimer’s drug, Aduhelm. 
Via InvestorPlace
Thinking About Buying Stock Or Options In Tilray, Ocugen, Biogen Or Snowflake?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
S&P 500 Hits Record High; Biogen Alzheimer's Drug, Tesla, Apple, RH, GameStop In Focus: Weekly Review
The S&P 500 hit a new high this week. The FDA OK'd a Biogen Alzheimer's drug. Tesla, Apple, RH, GameStop were in focus. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
Exposures Product Safety
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks. 
Via The Motley Fool
Exposures Product Safety
What 12 Analyst Ratings Have To Say About Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0 Somewhat... 
Via Benzinga
Biogen Gets an Unearned Rip on an Unproven Drug
Biogen will charge $56,000 for Aduhelm, although there's no guarantee it will work against Alzheimer's. That makes BIIB stock risky. 
Via InvestorPlace
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
Senator Takes Aim at Biogen's New Alzheimer's Drug
Sen. Ron Wyden calls Aduhelm's $56,000 price tag "unconscionable." 
Via The Motley Fool
Where Biogen Stands With Analysts
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 2 0 0 0 Somewhat... 
Via Benzinga
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer’s Disease. Not... 
Via Benzinga
Exposures Product Safety
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%. The Biogen Analysts:... 
Via Benzinga
Exposures Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
Thinking About Buying Stock Or Options In Target, Biogen Or Delta Air Lines?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2021
Upgrades According to Seaport Global, the prior rating for CMC Materials Inc (NASDAQ:CCMP) was changed from Neutral to Buy. CMC Materials earned $1.71 in the second... 
Via Benzinga
U.S. Approves Biogen's Alzheimer's Drug
During yesterday's session, the US pharmaceutical company based in Massachusetts, Biogen, experienced a strong rebound in the stock market after the FDA approved the use of its Alzheimer's drug known... 
Via Talk Markets
Exposures Product Safety
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Rosenblatt boosted Marvell Technology, Inc. (NASDAQ: MRVL) price target from $60 to $70. Marvell Technology shares rose 5.2% to $50.80 in pre-market trading. Jefferies raised... 
Via Benzinga
Could Biogen Be a Millionaire-Maker Stock?
A new Alzheimer's drug is entering the market thanks to Biogen. But we still don't know if it is truly effective. 
Via The Motley Fool
Exposures Product Safety
Should You Buy Biogen Stock After Its Stunning FDA Win?
There are still some risks for the biotech stock. But they're a lot lower now, with its Alzheimer's disease drug likely to make billions of dollars. 
Via The Motley Fool
Exposures Product Safety
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
Market Briefing For Tuesday, Jun. 8
Benign market behavior generally persists; as an out-of-the-box rally effort to start Monday was reversed, as is typical since traders want a pullback first. 
Via Talk Markets
Biogen CEO Says $56,000 Annual Price For Alzheimer's Drug Reflects 'Two Decades Of No Innovation'
Biogen Inc (NASDAQ: BIIB) CEO Michel Vounatsos has justified the annual $56,000 list price for its newly approved Alzheimer’s disease drug aducanumab as “fair,... 
Via Benzinga
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.